TIGIT Inhibitors Overview
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain.TIGIT inhibitors are a class of immunotherapy drugs designed to enhance the body's immune response against cancer. TIGIT, which stands for T-cell immunoreceptor with immunoglobulin and ITIM domain, is an immune checkpoint receptor found on various immune cells, including T cells and natural killer (NK) cells. Under normal circumstances, TIGIT helps regulate immune activity and prevent excessive immune responses. However, many tumors exploit this pathway to suppress immune cell function and evade detection.
TIGIT Inhibitors restore the activity of exhausted T cells and NK cells, enabling them to recognize and attack cancer cells more effectively. These agents are often studied in combination with other immune checkpoint inhibitors, particularly PD-1 or PD-L1 inhibitors, as dual blockade may produce stronger and more durable anti-tumor responses.
&nbsp;
TIGIT Inhibitors Therapies: 20+
&nbsp;
TIGIT Inhibitors Companies: 18+&nbsp;
&nbsp;
Key TIGIT Inhibitors Companies
<ul>
<li>Merck Sharp &amp; Dohme</li>
<li>Bristol-Myers Squibb</li>
<li>BeiGene</li>
<li>Arcus Biosciences</li>
<li>iTeos Therapeutics</li>
<li>Mereo BioPharma</li>
<li>Phio Pharmaceuticals</li>
<li>Bio-Thera Solutions</li>
<li>Compugen</li>
<li>And several others.</li>
</ul>
&nbsp;
TIGIT Inhibitors Report Assessment
<ul>
<li>Company Analysis</li>
<li>Therapeutic Assessment</li>
<li>Approved/Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
&nbsp;
Therapeutic Assessment:
<ul>
<li>By Product Type</li>
<li>By Stage and Product Type</li>
<li>By Route of Administration</li>
<li>By Stage and Route of Administration</li>
<li>By Molecule Type</li>
<li>By Stage and Molecule Type</li>
</ul>
&nbsp;
Related Reports:
TIGIT Inhibitors - Pipeline Insight, 2022

TIGIT Inhibitors Infographic

TIGIT Inhibitors Pipeline

TIGIT Inhibitors Infographic gives a brief about the treatment therapies, companies, overview and TIGIT Inhibitors report features.